Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MagTaT
- Development stage
- Preclinical
- Lead developer
- ChromoLogic
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
MagTaT is a preclinical-stage oral nanoparticle therapeutic being developed by ChromoLogic for the treatment of peripheral neuropathy (PN) and chronic pain. The drug candidate utilizes a proprietary nanoparticle delivery system designed to facilitate oral administration for neurological pain indications. As of the current development stage, ChromoLogic has not publicly disclosed the specific molecular target or the active pharmaceutical ingredient contained within the nanoparticle formulation. The program aims to address the need for effective, non-invasive treatments for chronic neuropathic pain conditions.
Beyond the preview
Go deeper on MagTaT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MagTaT.